CYP2C19基因型对舍曲林和艾司西酞普兰暴露及抗抑郁药换药率的影响:中国汉族患者回顾性队列研究
该回顾性队列研究纳入中国汉族患者,分析CYP2C19基因型对舍曲林和艾司西酞普兰血清浓度及抗抑郁药换药率的影响。与正常代谢型相比,慢代谢型和中间代谢型患者舍曲林和艾司西酞普兰血清浓度显著升高,且换药率显著增加。提示用药前进行CYP2C19基因分型具有临床获益。
要点
- CYP2C19慢代谢型患者舍曲林血清浓度较正常代谢型升高2倍,中间代谢型升高1.3倍。
- CYP2C19慢代谢型患者艾司西酞普兰血清浓度较正常代谢型升高2倍,中间代谢型升高1.2倍。
- CYP2C19慢代谢型和中间代谢型患者舍曲林换药率分别升高5.8倍和2.8倍。
核心结论
- CYP2C19基因型对舍曲林和艾司西酞普兰的暴露及抗抑郁药换药率有显著影响。
- 用药前进行CYP2C19基因分型在临床上具有获益。
研究设计与样本
- 回顾性队列研究,纳入中国汉族患者,来自河北医科大学第一医院治疗药物监测数据库。
- 共纳入415例患者的525次舍曲林血清浓度测定和294例患者的355次艾司西酞普兰血清浓度测定。
- 按CYP2C19基因型分为正常代谢型(NMs)、快代谢型(RMs)、中间代谢型(IMs)和慢代谢型(PMs)四个亚组,以NMs为参照进行比较。
主要发现
- 与CYP2C19 NMs组相比,PMs组和IMs组舍曲林血清浓度分别显著升高2倍和1.3倍。
- 与CYP2C19 NMs组相比,PMs组和IMs组艾司西酞普兰血清浓度分别显著升高2倍和1.2倍。
- 与CYP2C19 NMs组相比,PMs组和IMs组舍曲林换药率分别显著升高5.8倍和2.8倍。
- 与CYP2C19 NMs组相比,RMs组、PMs组和IMs组艾司西酞普兰换药率分别升高13.1倍、3.7倍和2.4倍。
临床怎么用
- 临床使用舍曲林或艾司西酞普兰前,可考虑进行CYP2C19基因分型以评估暴露风险和换药风险。
- 对CYP2C19 PMs和IMs患者,应关注舍曲林和艾司西酞普兰血清浓度升高及换药率增加的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sertraline and escitalopram, commonly used antidepressants in clinical practice, are metabolized by the polymorphic CYP2C19 enzyme. In a large-scale Chinese Han cohort, this study comprehensively examines the influence of CYP2C19 genotype on sertraline and escitalopram exposure, while also evaluating genotype-associated antidepressant switching rates. A total of 525 serum concentration measurements of sertraline in 415 patients and 355 serum concentration measurements of escitalopram in 294 patients were retrospectively included from the therapeutic drug monitoring database of the First Hospital of Hebei Medical University. Patients were categorized into four subgroups based on CYP2C19 genotype: Normal metabolizers (NMs), Rapid metabolizers (RMs), Intermediate metabolizers (IMs), and Poor metabolizers (PMs). Differences in sertraline and escitalopram exposure and antidepressant switching rates were compared between the subgroups, with CYP2C19 NMs set as reference. Compared with the CYP2C19 NMs group, sertraline serum concentrations were significantly increased 2-fold and 1.3-fold in the CYP2C19 PMs and CYP2C19 IMs groups, respectively, and escitalopram serum concentrations were significantly increased 2-fold and 1.2-fold in the CYP2C19 PMs and CYP2C19 IMs groups, respectively. Compared to the CYP2C19 NMs group, the antidepressant switching rate of sertraline in the CYP2C19 PMs and CYP2C19 IMs groups was significantly increased 5.8-fold and 2.8-fold; the antidepressant switching rate of escitalopram in the CYP2C19 RMs, CYP2C19 PMs, and CYP2C19 IMs groups was increased 13.1-fold, 3.7-fold, and 2.4-fold, respectively. The CYP2C19 genotype exerts a substantial influence on the exposure and the antidepressant switching rate of sertraline and escitalopram. CYP2C19 genotyping prior to administering drugs is clinically beneficial.
引用
- Yan Y, Wang J, Wang D, et al. Impact of CYP2C19 Genotype on Sertraline and Escitalopram Exposure and Antidepressant Switching Rate: A Retrospective Cohort Study of Chinese Han Patients. Clin Pharmacol Ther. 2025. PMID: 40346857. doi:10.1002/cpt.3707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。